DE69435332D1 - Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen - Google Patents

Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen

Info

Publication number
DE69435332D1
DE69435332D1 DE69435332T DE69435332T DE69435332D1 DE 69435332 D1 DE69435332 D1 DE 69435332D1 DE 69435332 T DE69435332 T DE 69435332T DE 69435332 T DE69435332 T DE 69435332T DE 69435332 D1 DE69435332 D1 DE 69435332D1
Authority
DE
Germany
Prior art keywords
virus
particles
preparation
envelope protein
human papillomavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435332T
Other languages
English (en)
Inventor
Robert C Rose
William Bonnez
Richard C Reichman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26703787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69435332(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/028,517 external-priority patent/US8062642B1/en
Application filed by University of Rochester filed Critical University of Rochester
Application granted granted Critical
Publication of DE69435332D1 publication Critical patent/DE69435332D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69435332T 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen Expired - Lifetime DE69435332D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/028,517 US8062642B1 (en) 1993-03-09 1993-03-09 Production of papillomavirus capsid protein and virus-like particles
US20730994A 1994-03-07 1994-03-07

Publications (1)

Publication Number Publication Date
DE69435332D1 true DE69435332D1 (de) 2011-02-17

Family

ID=26703787

Family Applications (9)

Application Number Title Priority Date Filing Date
DE1994634383 Pending DE122007000014I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen
DE69435332T Expired - Lifetime DE69435332D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen
DE69435331T Expired - Lifetime DE69435331D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
DE69434383T Expired - Lifetime DE69434383T2 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE201112100018 Pending DE122011100018I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE05075369T Pending DE05075369T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
DE122007000090C Pending DE122007000090I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE122007000089C Pending DE122007000089I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE05075889T Pending DE05075889T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE1994634383 Pending DE122007000014I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papillomavirus Hüllprotein und virus-ähnlichen Teilchen

Family Applications After (7)

Application Number Title Priority Date Filing Date
DE69435331T Expired - Lifetime DE69435331D1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
DE69434383T Expired - Lifetime DE69434383T2 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE201112100018 Pending DE122011100018I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
DE05075369T Pending DE05075369T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
DE122007000090C Pending DE122007000090I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE122007000089C Pending DE122007000089I1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen
DE05075889T Pending DE05075889T1 (de) 1993-03-09 1994-03-08 Herstellung von menschlichem Papilloma-Virus HBV-11-Capsid-Protein L1 und virusähnlichen Teilchen

Country Status (14)

Country Link
EP (3) EP0688227B1 (de)
JP (4) JPH08507685A (de)
AT (3) ATE492289T1 (de)
AU (3) AU688759C (de)
CA (1) CA2157932C (de)
DE (9) DE122007000014I1 (de)
DK (2) DK1618888T3 (de)
ES (3) ES2263406T3 (de)
FR (1) FR11C0022I2 (de)
HK (2) HK1082196A1 (de)
LU (3) LU91313I2 (de)
NL (3) NL300265I2 (de)
PT (2) PT688227E (de)
WO (1) WO1994020137A1 (de)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476389B1 (en) 1991-07-19 2009-01-13 The University Of Queensland Papillomavirus vaccines
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
EP1728800A1 (de) * 1994-10-07 2006-12-06 Loyola University Of Chicago Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
ES2213185T3 (es) * 1995-11-15 2004-08-16 MERCK & CO., INC. Particulas de tipo virus hpv11 sinteticas.
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
EP0956349B1 (de) * 1996-10-04 2003-12-17 Merck & Co., Inc. (a New Jersey corp.) Synthetische hpv16 virus-ähnliche partikel
WO1998025646A1 (en) * 1996-12-09 1998-06-18 Merck & Co., Inc. Synthetic hpv16 virus-like particles
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
EP1319089B1 (de) * 2000-09-18 2010-12-01 MedImmune, LLC In vitro testverfahren zur bestimmung der immunogenizität eines impfstoffes
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
EP1425423B1 (de) 2001-08-13 2010-06-23 University of Rochester Transkutane immunisierung gegen papillomavirus mit virusähnlichen papillomaviruspartikeln
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
WO2006065166A1 (fr) * 2005-07-26 2006-06-22 Obschestvo S Ogranichennoi Otvetstvennostyu 'rusgen' Composition de traitement et de prevention de l'infection de l'humain par le papillomavirus sur la base de la proteine l1 et des peptides de la proteine e7
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8778351B2 (en) 2006-08-30 2014-07-15 University Of Rochester Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
TR201807756T4 (tr) 2006-09-26 2018-06-21 Infectious Disease Res Inst Sentetik adjuvan içeren aşı bileşimi.
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
MX2009009342A (es) 2007-03-02 2009-09-11 Glaxosmithkline Biolog Sa Metodo novedoso y composiciones.
WO2008134935A1 (fr) 2007-04-29 2008-11-13 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Protéines 18 l1 de type papillomavirus humain tronqué
BRPI0811016B1 (pt) * 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
EP2154148B1 (de) 2007-05-29 2016-06-22 Xiamen University Verkürztes l1-protein des humanen papillomavirus 11
BRPI0810951B8 (pt) 2007-05-29 2021-05-25 Beijing Wantai Biological Pharmacy Entpr Co Ltd proteína l1 do hpv6, polinucleotídeo, vetor, célula, partícula semelhante ao vírus (vlp) hpv6, método para produzir a proteína hpv6 l1 truncada, vacina para prevenção de condiloma acuminado ou de infecções por hpv, uso da proteína hpv6 l1 truncada, método para prevenção de condiloma acuminado ou infecções por hpv, método para obter uma vlp de uma proteína l1 do hpv6 e método para produzir uma vacina para a prevenção de condiloma acuminado ou de infecções por hpv
US20110091496A1 (en) * 2008-01-19 2011-04-21 Graham Barney S Methods and compositions for the delivery of vaccines to disrupted epithelium
EA027784B1 (ru) 2008-05-26 2017-09-29 Кадила Хелзкэр Лимитед Комбинированная вакцина против кори и вируса папилломы человека
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
US20120115207A1 (en) * 2009-04-03 2012-05-10 Deutsches Krebsforschungszentrum Enhanced production of papillomavirus-like particles with a modified baculovirus expression system
EP2437753B1 (de) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen die diese enthalten
WO2011026111A1 (en) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP3730943A1 (de) 2010-04-08 2020-10-28 University of Pittsburgh - Of the Commonwealth System of Higher Education Zellenassay mit b-zellen-antigenen
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN104363892A (zh) 2012-02-07 2015-02-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
US20150110824A1 (en) 2012-03-18 2015-04-23 Glaxosmithkline Biologicals, Sa Method of vaccination against human papillomavirus
RS57420B1 (sr) 2012-05-16 2018-09-28 Immune Design Corp Vakcine za hsv-2
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CA2909221A1 (en) 2013-04-18 2014-10-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US11801223B2 (en) 2013-12-31 2023-10-31 Access To Advanced Health Institute Single vial vaccine formulations
CA3010905A1 (en) 2016-02-22 2017-08-31 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
CN109562057A (zh) 2016-05-16 2019-04-02 传染病研究所 聚乙二醇化脂质体和使用方法
IL314130A (en) 2016-05-16 2024-09-01 Access To Advanced Health Inst Formulation containing a TLR agonist and methods of use
BR112018074352B1 (pt) 2016-06-01 2021-11-30 Infectious Disease Research Institute Partículas de nanoalume contendo um agente de dimensionamento
KR102673794B1 (ko) 2017-06-15 2024-06-11 액세스 투 어드밴스드 헬스 인스티튜트 나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022171681A1 (en) 2021-02-11 2022-08-18 Glaxosmithkline Biologicals Sa Hpv vaccine manufacture
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
CN116375816B (zh) * 2023-01-06 2023-09-05 北京康乐卫士生物技术股份有限公司 一种人乳头瘤病毒56型l1蛋白突变体及减少重组蛋白降解的方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956288A (en) * 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
NZ232913A (en) * 1989-03-15 1992-08-26 Gist Brocades Nv Il-3 produced recombinantly and purified to homogeneity; vectors and pharmaceutical preparations
US7476389B1 (en) * 1991-07-19 2009-01-13 The University Of Queensland Papillomavirus vaccines

Also Published As

Publication number Publication date
EP1588713B1 (de) 2010-12-22
DE69434383T2 (de) 2005-11-24
EP1618888A1 (de) 2006-01-25
AU6443694A (en) 1994-09-26
AU2007201005A1 (en) 2007-03-29
DE05075369T1 (de) 2006-11-16
JP5386392B2 (ja) 2014-01-15
NL300309I1 (nl) 2008-02-01
DE122011100018I1 (de) 2011-11-17
AU2007201006A1 (en) 2007-03-29
JPH08507685A (ja) 1996-08-20
JP5306251B2 (ja) 2013-10-02
EP1618888B1 (de) 2011-01-05
ES2263405T3 (es) 2011-04-20
DK0688227T3 (da) 2005-06-27
HK1082196A1 (en) 2006-06-02
FR11C0022I2 (fr) 2012-08-03
ATE492289T1 (de) 2011-01-15
AU688759C (en) 2006-12-21
DE122007000089I1 (de) 2008-03-27
EP0688227A4 (de) 1996-05-29
DE69434383D1 (de) 2005-06-30
PT688227E (pt) 2005-10-31
JP2007075117A (ja) 2007-03-29
EP0688227A1 (de) 1995-12-27
AU688759B2 (en) 1998-03-19
NL300265I2 (nl) 2008-05-01
DE122007000090I1 (de) 2008-03-27
CA2157932C (en) 2011-10-11
ES2242955T4 (es) 2010-04-12
DE05075889T1 (de) 2006-10-05
LU91392I2 (fr) 2008-02-14
WO1994020137A1 (en) 1994-09-15
ES2263406T3 (es) 2011-06-06
PT1618888E (pt) 2011-04-08
HK1082206A1 (en) 2006-06-02
NL300310I1 (nl) 2008-02-01
LU91313I2 (fr) 2007-04-23
DK1618888T3 (da) 2011-04-04
NL300265I1 (nl) 2007-05-01
CA2157932A1 (en) 1994-09-15
JP4486075B2 (ja) 2010-06-23
FR11C0022I1 (de) 2011-05-08
ES2263406T1 (es) 2006-12-16
ES2242955T3 (es) 2005-11-16
DE69435331D1 (de) 2011-02-03
AU2007201006B2 (en) 2010-07-01
EP1588713A1 (de) 2005-10-26
LU91391I2 (fr) 2008-02-14
JP2010099091A (ja) 2010-05-06
ES2263405T1 (es) 2006-12-16
NL300309I2 (nl) 2008-03-03
DE122007000014I1 (de) 2007-05-24
AU2007201005B2 (en) 2010-06-10
EP0688227B1 (de) 2005-05-25
ATE494005T1 (de) 2011-01-15
ATE296111T1 (de) 2005-06-15
JP2010148514A (ja) 2010-07-08

Similar Documents

Publication Publication Date Title
DE69435332D1 (de) Herstellung von menschlichem Papillomaviren Hüllprotein und Virus-ähnlichen Teilchen
DK0809700T3 (da) Papillomaviruslignende partikler, fusionsproteiner samt fremgangsmåde til fremstilling heraf
DE69535018D1 (de) Papillomavirus vakzine
ATE288489T1 (de) Vp-antigene des jc-virus
EP0868522A4 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, zusammensetzungen dessen und methoden zur herstellung und verwendung
DK0750669T3 (da) Modificeret papillomavirus-L2-protein og VLP'er dannet derudfra
ATE290093T1 (de) EXPRIMIERUNG EINES MODIFIZIERTEM ßFOAMY VIRUS ENVELOPE PROTEINß (HÜLLENPROTEIN)